Chengdu, China, December 28, 2025 – Chengdu New Radiomedicine Technology Co., Ltd. (“NRT”) is excited to announce the company has received approval of Radiation Safety License for its two new state-of-the-art facilities: Cyclone® IKON, a 30MeV cyclotron by IBA and 99Mo/99mTc generator production line, authorizing full operational commencement. This pivotal regulatory achievement marks the transition from commissioning to commercial production, enabling NRT to begin manufacturing of more critical diagnostic and therapeutic radioisotopes, including 68Ge, 225Ac, 123I, 18F, 64Cu, 111In, 89Zr and 99mTc.
The license, issued by China Ministry of Ecology and Environment, demonstrates that NRT’s facilities, protocols, and operational procedures meet the stringent standards for safe production of radioactive materials. It also validates years of meticulous planning and dedication by NRT team, and underscores the company’s unwavering commitment to safety, quality, and regulatory compliance as a foundational pillar of its operations.
With addition of the two new facilities to its current manufacturing sites, which have been producing radioisotopes and radiopharmaceutical products including 68Ga generator, 90Y chloride solution, and 99mTc-labeled drugs, NRT is well positioned as a reliable radioactive product supplier, strengthening the supply chain to support our clients and partners on their important initiatives in radiopharmaceutical innovation.
**About NRT**
Chengdu New Radiomedicine Technology Co., Ltd. (“NRT”), founded in 2016 by veterans in nuclear technology, focuses on the full value chain of medical isotopes production and radiopharmaceutical innovation. The company has multiple branches in China and global presence in the United States and Australia. Our team of 300+ professionals delivers integrated solutions from radiopharmaceutical discovery to global commercialization.
Leveraging rich expertise in nuclear medicine and drug innovation, our cross-disciplinary team of radiochemists, clinical researchers and regulatory experts work together to accelerate radioligand therapy (RLT) advancement. The iCleave™ Technology Platform develops purposely-designed linkers for RLT, optimizing bio-distribution, safety and efficacy. The 68Ga- and 177Lu-NRT6020 Injections for diagnosis and treatment of FAP-positive advanced solid tumors, respectively, have obtained FDA IND clearance and NMPA IND approval, with Phase I patient enrollment in progress. NRT’s proprietary 90Y Carbon Microspheres in late phase clinical development for liver and pancreatic cancers deliver safe and highly effective treatment options to patients using minimally invasive procedures. Additionally, NRT has completed installation of the first 30MeV Cyclone® IKON in Asia and is ready for production of important therapeutic and imaging isotopes.
NRT is committed to becoming a leading enterprise in the field of innovative radiopharmaceutical development.
